Recently, Shanghai UniXell Biotechnology Co., Ltd. (“UniXell Bio”) announced the completion of an over RMB 50 million Series A+ financing round. This round was jointly led by Panlin Capital, Thevillages Investment, and Waigaoqiao Private Equity Fund. The proceeds will be used to accelerate the clinical development of the company’s off-the-shelf cell therapy pipelines for Parkinson’s disease and epilepsy, as well as to further advance the scalable development and industrialization of innovative cell therapeutics. Combined with the previously completed Series A financing—jointly backed by investors including Tasly Pharmaceutical and SDIC Pioneer Fund—the company’s total Series A financing has reached RMB 300 million.

This milestone reflects strong recognition from both the capital market and government entities of UniXell Bio’s scientific approach, the certainty of its R&D progress, and its long-term commercial potential amid the current biotech investment landscape. As the first cell therapy company directly invested in by the SDIC Pioneer Fund, UniXell Bio has received financial support from multiple levels of government, including Pudong New Area and the Waigaoqiao Free Trade Zone. The company has also attracted leading market-oriented venture capital firms represented by Panlin Capital, as well as top-tier industrial partners such as Tasly Pharmaceutical, forming a synergistic investor base that integrates market capital, industrial capital, and state-owned capital.

UniXell Bio is a biotechnology company dedicated to the development of innovative stem cell-based therapeutics. Leveraging its globally leading high-throughput lineage tracing technology and iPSC derivation and differentiation platform, the company continues to maintain a technological edge in the field. As one of the few companies worldwide with end-to-end capabilities spanning the development and scalable manufacturing of multiple types of iPSC-derived cell therapies, UniXell Bio demonstrates strong technological depth and broad application potential.

Among its pipeline assets, the company’s proprietary product, UX-DA001, has become the world’s first autologous cell therapy for Parkinson’s disease to achieve dual IND approvals in China and the United States, and has been granted Fast Track designation by the U.S. FDA. The product is currently undergoing a Phase I registrational clinical trial at Ruijin Hospital, Shanghai Jiao Tong University School of Medicine. Multiple patients have already received cell transplantation, with follow-up data indicating favorable safety and tolerability, along with encouraging preliminary efficacy signals, laying a solid foundation for the advancement of subsequent clinical programs across the pipeline.